1. Home
  2. NAMSW vs GENE Comparison

NAMSW vs GENE Comparison

Compare NAMSW & GENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMSW
  • GENE
  • Stock Information
  • Founded
  • NAMSW N/A
  • GENE 1989
  • Country
  • NAMSW Netherlands
  • GENE Australia
  • Employees
  • NAMSW 29
  • GENE N/A
  • Industry
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • GENE Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NAMSW Health Care
  • GENE Health Care
  • Exchange
  • NAMSW Nasdaq
  • GENE Nasdaq
  • Market Cap
  • NAMSW N/A
  • GENE N/A
  • IPO Year
  • NAMSW N/A
  • GENE N/A
  • Fundamental
  • Price
  • NAMSW $9.00
  • GENE $0.81
  • Analyst Decision
  • NAMSW
  • GENE
  • Analyst Count
  • NAMSW 0
  • GENE 0
  • Target Price
  • NAMSW N/A
  • GENE N/A
  • AVG Volume (30 Days)
  • NAMSW N/A
  • GENE 91.9K
  • Earning Date
  • NAMSW N/A
  • GENE 08-13-2024
  • Dividend Yield
  • NAMSW N/A
  • GENE N/A
  • EPS Growth
  • NAMSW N/A
  • GENE N/A
  • EPS
  • NAMSW N/A
  • GENE N/A
  • Revenue
  • NAMSW N/A
  • GENE $5,776,090.00
  • Revenue This Year
  • NAMSW N/A
  • GENE N/A
  • Revenue Next Year
  • NAMSW N/A
  • GENE N/A
  • P/E Ratio
  • NAMSW N/A
  • GENE N/A
  • Revenue Growth
  • NAMSW N/A
  • GENE 293.98
  • 52 Week Low
  • NAMSW N/A
  • GENE $0.75
  • 52 Week High
  • NAMSW N/A
  • GENE $4.70
  • Technical
  • Relative Strength Index (RSI)
  • NAMSW 47.49
  • GENE 22.61
  • Support Level
  • NAMSW $9.40
  • GENE $0.87
  • Resistance Level
  • NAMSW $10.14
  • GENE $1.51
  • Average True Range (ATR)
  • NAMSW 0.44
  • GENE 0.15
  • MACD
  • NAMSW -0.12
  • GENE -0.02
  • Stochastic Oscillator
  • NAMSW 24.31
  • GENE 6.77

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: